Colonic Diseases [C06.405.469.158] Clinical Trial
Official title:
Effect of Galacto-Oligosaccharides Supplementation on Amoxicillin-treated Gut Microbiota From Healthy Adults : a Proof of Principal Study
Prebiotics are thought to be a potential means to prevent antibiotic-associated diarrhoea
because of their ability to stimulate beneficial bacteria. In-vitro results showed a
promising recovery of Bifidobacteria combined with an increase of Short Chain Fatty Acids
(SCFA) upon Galacto-oligosaccharides (GOS) supplementation to amoxicillin-treated
microbiota. As the microbiota is nowadays considered as a key factor in human health, a
further understanding of the gut microbiota functioning in-vivo is essential. This
understanding of the use of specific prebiotics may possibly be beneficial in the prevention
or recovery of antibiotic-disturbed microbiota. As the effects of GOS supplementation on the
microbiota composition and activity from healthy adults receiving amoxicillin have never
been tested in-vivo, the investigators propose the current study as a proof of principle.
Objective:
To explore whether the promising effects of GOS supplementation on the composition and
activity of gut microbiota from healthy adults as found by in-vitro, can also be observed
in-vivo.
Study population:
10 healthy men and women volunteers, 18 - 40 yr old
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment